United Therapeutics Corporation (UTHR) shares surged approximately 28.5% after the company announced that the U.S. District Court for the District of New Jersey has rendered a favorable decision in the Remodulin patent infringement lawsuit against Sandoz, the generic division of Novartis (NVS). As per the court’s ruling, Sandoz will not be able to launch its…
The biotech sector had a strong run last week thanks mostly to Roche’s agreement to acquire InterMune (ITMN) for a hefty $8.3 billion. The announcement of this deal resulted in a spike in the share price of quite a few mid-cap biotech companies that are considered to be lucrative acquisition targets. The week’s most important…
Biotech is back. This spring, biotech stocks collapsed. The Nasdaq Biotechnology Index tumbled 22% in about six weeks, inflicting huge losses on hedge funds and other investors, including holders of a popular exchange-traded fund known for its ticker “IBB,” the iShares Nasdaq Biotechnology ETF , which has about $5.5 billion in assets. So far in…
Regado Biosciences, Inc (RGDO) announced that it is permanently terminating the enrollment process for its phase III REGULATE-PCI study on Revolixys Kit. Regado’s shares tumbled over 60% on the news. Regado was dealt a severe blow with the Data and Safety Monitoring Board for a late-stage study recommending the permanent termination of patient enrolment. The…
On Monday morning, it was announced that Avago Technologies (AVGO), a leader in advanced optical, analog and mixed-signal chip design, will acquire LSI Corp (LSI), a strong market participant in hard disk drive semiconductor, system-level silicon for communications and server applications and flash storage solutions. AVGO will pay $6.6 billion for LSI, or $11.15 per…
ARM Holdings reported 3Q13 results on Thursday that were above consensus estimates. On a positive note, ARMH’s license revenue continues to significantly exceed expectations, and ARM PD (Processor Division) royalty revenue continues to outperform ARM’s served available market (SAM) according to management’s guidance. Admittedly, shares are richly valued, and the market clearly wanted a perfect…
